DexCom Receives New Coverage from Analysts at Benchmark Co. (DXCM)
Equities researchers at Benchmark Co. started coverage on shares of DexCom (NYSE:DXCM) in a research report issued on Tuesday, Analyst Ratings Net reports. The firm set a “buy” rating and a $37.00 price target on the stock. Benchmark Co.’s price objective points to a potential upside of 25.55% from the company’s current price.
DXCM has been the subject of a number of other recent research reports. Analysts at Raymond James raised their price target on shares of DexCom from $26.00 to $31.00 in a research note to investors on Monday. They now have an “outperform” rating on the stock. Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of DexCom in a research note to investors on Friday, September 13th. They set an “overweight” rating and a $32.00 price target on the stock. Finally, analysts at Wedbush raised their price target on shares of DexCom from $18.00 to $31.00 in a research note to investors on Tuesday, August 13th. They now have an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $26.13.
Shares of DexCom (NYSE:DXCM) traded up 1.48% during mid-day trading on Tuesday, hitting $29.47. The stock had a trading volume of 1,029,632 shares. DexCom has a 52-week low of $12.03 and a 52-week high of $29.24. The stock has a 50-day moving average of $27.62 and a 200-day moving average of $22.65. The company’s market cap is $2.103 billion.
DexCom, Inc is a medical device company. The Company focuses on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.